

This material is an English translation of the press release announced on October 22, 2018 in Japanese, and the Japanese release is given priority about the content and the interpretation.

October 22, 2018

Notification of the commencement of the Phase II clinical study of HP-5070 in Japan (a transdermal drug for the treatment of primary local hyperhidrosis)

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga Prefecture, Japan; Chairman and CEO: Hirotaka Nakatomi) hereby announces that it has commenced of the Phase II clinical study for “primary local hyperhidrosis” in Japan (Development code: HP-5070, hereinafter referred to as “the product”).

In the Phase II clinical study, the efficacy and safety of administration of the product will be compared with a placebo in patients with primary local hyperhidrosis.

In the future, we aim to initiate a Phase III clinical study during FY 2020.